Bruno Marques
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Bruno Marques has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
Alexander Hanke
Pall Life Sciences, Portsmouth, United Kingdom
1 shared publicationAmbrose Williams
Genentech Inc, South San Francisco, CA, USA
1 shared publication- Ana Villegas-Mendez
Faculty of Life Sciences, University of Manchester, Manchester, United Kingdom
1 shared publication - Barry Morse
Research and Development, Century Therapeutics, Philadelphia, PA 19104, USA
1 shared publication Benjamin Walters
Genentech Inc, South San Francisco, CA, USA
1 shared publication- Carl J. Burke
Process and Product Development, Century Therapeutics, Philadelphia, PA 19104, USA
1 shared publication
Latest Publications
- Open Access
Role of Cytokines and Growth Factors in the Manufacturing of iPSC-Derived Allogeneic Cell Therapy Products
Cytokines and other growth factors are essential for cell expansion, health, function, and immune stimulation. Stem cells have the additional reliance on these factors to direct differentiation to the appropriate terminal cell type. Successful manufacturing of allogeneic cell therapies from induced pluripotent stem cells (iPSCs) requires close attention to the selection and control of cytokines and factors used throughout the manufacturing process, as well as after administration to the patient. This paper employs iPSC-derived natural killer cell/T cell therapeutics to illustrate the use of cytokines, growth factors, and transcription factors at different stages of the manufacturing process, ranging from the generation of iPSCs to controlling of iPSC differentiation into immune-effector cells through the support of cell therapy after patient administration.
Open AccessRole of Cytokines and Growth Factors in the Manufacturing of iPSC-Derived Allogeneic Cell Therapy Products
Cytokines and other growth factors are essential for cell expansion, health, function, and immune stimulation. Stem cells have the additional reliance on these factors to direct differentiation to the appropriate terminal cell type. Successful manufacturing of allogeneic cell therapies from induced pluripotent stem cells (iPSCs) requires close attention to the selection and control of cytokines and factors used throughout the manufacturing process, as well as after administration to the patient. This paper employs iPSC-derived natural killer cell/T cell therapeutics to illustrate the use of cytokines, growth factors, and transcription factors at different stages of the manufacturing process, ranging from the generation of iPSCs to controlling of iPSC differentiation into immune-effector cells through the support of cell therapy after patient administration.
- 7 April 2020
- Published by Wiley in Biotechnology and Bioengineering
- Vol. 117 (7) , 2100-2115
Highland games: A benchmarking exercise in predicting biophysical and drug properties of monoclonal antibodies from amino acid sequences
Biopharmaceutical product and process development does not yet take advantage of predictive computational modeling to nearly the degree seen in industries based on smaller molecules. To assess and advance progress in this area, spirited coopetition (mutually‐beneficial collaboration between competitors) was successfully used to motivate industrial scientists to develop, share, and compare data and methods which would normally have remained confidential. The first “Highland Games” competition was held in conjunction with the October 2018 Recovery of Biological Products Conference in Ashville, NC, USA, with the goal of benchmarking and assessment of the ability to predict development‐related properties of six antibodies from their amino acid sequences alone. Predictions included purification‐influencing properties such as isoelectric point and Protein A elution pH, and biophysical properties such as stability and viscosity at very high concentrations. Essential contributions were made by a large variety of individuals, including companies which consented to provide antibody amino acid sequences and test materials, volunteers who undertook the preparation and experimental characterization of these materials, and prediction teams who attempted to predict antibody properties from sequence alone. Best practices were identified and shared, and areas in which the community excels at making predictions were identified, as well as areas presenting opportunities for considerable improvement. Predictions of isoelectric point and Protein A elution pH were especially good with all‐prediction average errors of 0.2 and 1.6 pH unit, respectively, while predictions of some other properties were notably less good. This manuscript presents the events, methods, and results of the competition, and can serve as a tutorial and as a reference for in‐house benchmarking by others. Organizations vary in their policies concerning disclosure of methods, but most managements were very cooperative with the Highland Games exercise, and considerable insight into common and best practices is available from the contributed methods. The accumulated data set will serve as a benchmarking tool for further development of in silico prediction tools.
- 7 April 2020
- Published by Wiley in Biotechnology and Bioengineering
- Vol. 117 (7) , 2100-2115
Highland games: A benchmarking exercise in predicting biophysical and drug properties of monoclonal antibodies from amino acid sequences
Biopharmaceutical product and process development does not yet take advantage of predictive computational modeling to nearly the degree seen in industries based on smaller molecules. To assess and advance progress in this area, spirited coopetition (mutually‐beneficial collaboration between competitors) was successfully used to motivate industrial scientists to develop, share, and compare data and methods which would normally have remained confidential. The first “Highland Games” competition was held in conjunction with the October 2018 Recovery of Biological Products Conference in Ashville, NC, USA, with the goal of benchmarking and assessment of the ability to predict development‐related properties of six antibodies from their amino acid sequences alone. Predictions included purification‐influencing properties such as isoelectric point and Protein A elution pH, and biophysical properties such as stability and viscosity at very high concentrations. Essential contributions were made by a large variety of individuals, including companies which consented to provide antibody amino acid sequences and test materials, volunteers who undertook the preparation and experimental characterization of these materials, and prediction teams who attempted to predict antibody properties from sequence alone. Best practices were identified and shared, and areas in which the community excels at making predictions were identified, as well as areas presenting opportunities for considerable improvement. Predictions of isoelectric point and Protein A elution pH were especially good with all‐prediction average errors of 0.2 and 1.6 pH unit, respectively, while predictions of some other properties were notably less good. This manuscript presents the events, methods, and results of the competition, and can serve as a tutorial and as a reference for in‐house benchmarking by others. Organizations vary in their policies concerning disclosure of methods, but most managements were very cooperative with the Highland Games exercise, and considerable insight into common and best practices is available from the contributed methods. The accumulated data set will serve as a benchmarking tool for further development of in silico prediction tools.
- 1 March 2008
- Published by Elsevier in Journal of Controlled Release
- Vol. 126 (3) , 217-227
Liposomes-mediated delivery of pro-apoptotic therapeutic membrane proteins
- 1 March 2008
- Published by Elsevier in Journal of Controlled Release
- Vol. 126 (3) , 217-227
Liposomes-mediated delivery of pro-apoptotic therapeutic membrane proteins